Radiation Oncology | |
Effects of ionizing radiation in combination with Erufosine on T98G glioblastoma xenograft tumours: a study in NMRI nu/nu mice | |
Verena Jendrossek5  Wilfried Budach6  Claus Belka1  Michael Bamberg2  Hansjörg Eibl4  Lars H Lindner3  Verena Meier2  Guido Henke2  | |
[1] Department of Radiooncology, University Hospital Grosshadern, Ludwig-Maximilians-University, Marchionistr.15, München, 81377, Germany;Department of Radiooncology, University Hospital Tübingen, Hoppe-Seyler-Str. 3, Tübingen, 72076, Germany;Department of Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University, Marchionistr.15, München, 81377, Germany;Max-Planck-Institute for Biophysical Chemistry, Am Fassberg 11, Göttingen, 37077, Germany;Department of Molecular Cell Biology, Institute of Cell Biology (Cancer Research), University Hospital Essen, Virchowstrasse 173, Essen, 45122, Germany;Department of Radiooncology, University Hospital Düsseldorf, Moorenstrasse 5, Düsseldorf, 40225, Germany | |
关键词: Local control; Mouse model; Xenograft tumours; T98G glioblastoma; Combination therapy; Radiotherapy; Erufosine; | |
Others : 1155203 DOI : 10.1186/1748-717X-7-172 |
|
received in 2012-07-12, accepted in 2012-10-13, 发布年份 2012 | |
【 摘 要 】
Background
Erufosine is a promising anticancer drug that increases the efficacy of radiotherapy in glioblastoma cell lines in vitro. Moreover, treatment of nude mice with repeated intraperitoneal or subcutaneous injections of Erufosine is well tolerated and yields drug concentrations in the brain tissue that are higher than the concentrations required for cytotoxic drug effects on glioblastoma cell lines in vitro.
Methods
In the present study we aimed to evaluate the effects of a combined treatment with radiotherapy and Erufosine on growth and local control of T98G subcutaneous glioblastoma xenograft-tumours in NMRI nu/nu mice.
Results
We show that repeated intraperitoneal injections of Erufosine resulted in a significant drug accumulation in T98G xenograft tumours on NMRI nu/nu mice. Moreover, short-term treatment with 5 intraperitoneal Erufosine injections caused a transient decrease in the growth of T98G tumours without radiotherapy. Furthermore, an increased radiation-induced growth delay of T98G xenograft tumours was observed when fractionated irradiation was combined with short-term Erufosine-treatment. However, no beneficial drug effects on fractionated radiotherapy in terms of local tumour control were observed.
Conclusions
We conclude that short-term treatment with Erufosine is not sufficient to significantly improve local control in combination with radiotherapy in T98G glioblastoma xenograft tumours. Further studies are needed to evaluate efficacy of extended drug treatment schedules.
【 授权许可】
2012 Henke et al.; licensee BioMed Central Ltd.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
20150407112830857.pdf | 833KB | download | |
Figure 5. | 97KB | Image | download |
Figure 4. | 71KB | Image | download |
Figure 3. | 78KB | Image | download |
Figure 2. | 57KB | Image | download |
Figure 1. | 96KB | Image | download |
【 图 表 】
Figure 1.
Figure 2.
Figure 3.
Figure 4.
Figure 5.
【 参考文献 】
- [1]Henke G, Lindner LH, Vogeser M, Eibl HJ, Worner J, Muller AC, Bamberg M, Wachholz K, Belka C, Jendrossek V: Pharmacokinetics and biodistribution of Erufosine in nude mice--implications for combination with radiotherapy. Radiation Oncology (London, England) 2009, 4:46.
- [2]Erdlenbruch B, Jendrossek V, Gerriets A, Vetterlein F, Eibl H, Lakomek M: Erucylphosphocholine: pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration. Cancer Chemotherapy and Pharmacology 1999, 44(6):484-490.
- [3]Rubel A, Handrick R, Lindner LH, Steiger M, Eibl H, Budach W, Belka C, Jendrossek V: The membrane targeted apoptosis modulators erucylphosphocholine and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro. Radiation Oncology (London, England) 2006, 1:6.
- [4]Lawrence TS, Blackstock AW, McGinn C: The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol 2003, 13(1):13-21.
- [5]Handrick R, Rubel A, Faltin H, Eibl H, Belka C, Jendrossek V: Increased cytotoxicity of ionizing radiation in combination with membrane-targeted apoptosis modulators involves downregulation of protein kinase B/Akt-mediated survival-signaling. Radiother Oncol 2006, 80(2):199-206.
- [6]Ruiter GA, Zerp SF, Bartelink H, van Blitterswijk WJ, Verheij M: Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anti-cancer drugs 2003, 14(2):167-173.
- [7]Rudner J, Ruiner CE, Handrick R, Eibl HJ, Belka C, Jendrossek V: The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation. Radiation Oncology (London, England) 2010, 5:108.
- [8]Ruiter GA, Zerp SF, Bartelink H, van Blitterswijk WJ, Verheij M: Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res 1999, 59(10):2457-2463.
- [9]Jendrossek V, Handrick R: Membrane targeted anticancer drugs: potent inducers of apoptosis and putative radiosensitisers. Curr Med Chem 2003, 3(5):343-353.
- [10]Vink SR, van Blitterswijk WJ, Schellens JH, Verheij M: Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy. Cancer Treatment Rev 2007, 33(2):191-202.
- [11]Verweij J, Planting A, van der Burg M, Stoter G: A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours. J Cancer Res Clin Oncol 1992, 118(8):606-608.
- [12]Unger C, Berdel W, Hanauske AR, Sindermann H, Engel J, Mross K: First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. Eur J Cancer 2010, 46(5):920-925.
- [13]Van Ummersen L, Binger K, Volkman J, Marnocha R, Tutsch K, Kolesar J, Arzoomanian R, Alberti D, Wilding G: A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 2004, 10(22):7450-7456.
- [14]Lindner LH, Eibl H, Hossann M, Vogeser M: Quantification of erufosine, the first intravenously applicable alkylphosphocholine, in human plasma by isotope dilution liquid chromatography-tandem mass spectrometry using a deuterated internal standard. J Chromatogr B Analyt Technol Biomed Life Sci 2008, 869(1–2):16-19.
- [15]Vink SR, Schellens JH, Beijnen JH, Sindermann H, Engel J, Dubbelman R, Moppi G, Hillebrand MJ, Bartelink H, Verheij M: Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. Radiother Oncol 2006, 80(2):207-213.
- [16]Bendell JC, Nemunaitis J, Vukelja SJ, Hagenstad C, Campos LT, Hermann RC, Sportelli P, Gardner L, Richards DA: Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer. J Clinical Oncology: Official J Am Soc Clinical Oncology 2011, 29(33):4394-4400.
- [17]Mollinedo F: Antitumor ether lipids: proapoptotic agents wth multiple therapeutic indications. Expert Opin Ther Patents 2007, 17(4):385-405.
- [18]Stuben G, Budach W, Schick KH, Stuschke M, Stapper N, Muller S, Feldmann HJ: A time-saving system for irradiations of experimental tumors. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al.] 1994, 170(1):36-41.
- [19]Walker AM, Suit HD: Assessment of local tumor control using censored tumor response data. Int J Radiat Oncol Biol Phys 1983, 9(3):383-386.
- [20]Sachs L, Heddereich J: Angewandte Statistik. 13. Berlin: Springer; 2009.
- [21]Vink SR, Schellens JH, van Blitterswijk WJ, Verheij M: Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Investigational New Drugs 2005, 23(4):279-286.
- [22]de la Pena L, Burgan WE, Carter DJ, Hollingshead MG, Satyamitra M, Camphausen K, Tofilon PJ: Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells. Mol Cancer Ther 2006, 5(6):1504-1510.
- [23]Li Z, Tan F, Liewehr DJ, Steinberg SM, Thiele CJ: In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine. J Natl Cancer Inst 2010, 102(11):758-770.
- [24]Gao Y, Ishiyama H, Sun M, Brinkman KL, Wang X, Zhu J, Mai W, Huang Y, Floryk D, Ittmann M, et al.: The alkylphospholipid, perifosine, radiosensitizes prostate cancer cells both in vitro and in vivo. Radiation oncology (London, England) 2011, 6:39.
- [25]Marsh Rde W, Rocha Lima CM, Levy DE, Mitchell EP, Rowland KM Jr, Benson AB 3rd: A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am J Clin Oncology 2007, 30(1):26-31.
- [26]Argiris A, Cohen E, Karrison T, Esparaz B, Mauer A, Ansari R, Wong S, Lu Y, Pins M, Dancey J, et al.: A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biology & Therapy 2006, 5(7):766-770.
- [27]Leighl NB, Dent S, Clemons M, Vandenberg TA, Tozer R, Warr DG, Crump RM, Hedley D, Pond GR, Dancey JE, et al.: A Phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Res Treatment 2008, 108(1):87-92.
- [28]Ernst DS, Eisenhauer E, Wainman N, Davis M, Lohmann R, Baetz T, Belanger K, Smylie M: Phase II study of perifosine in previously untreated patients with metastatic melanoma. Investigational New Drugs 2005, 23(6):569-575.
- [29]Ghobrial IM, Roccaro A, Hong F, Weller E, Rubin N, Leduc R, Rourke M, Chuma S, Sacco A, Jia X, et al.: Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res 2010, 16(3):1033-1041.
- [30]Bailey HH, Mahoney MR, Ettinger DS, Maples WJ, Fracasso PM, Traynor AM, Erlichman C, Okuno SH: Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. Cancer 2006, 107(10):2462-2467.
- [31]Chee KG, Longmate J, Quinn DI, Chatta G, Pinski J, Twardowski P, Pan CX, Cambio A, Evans CP, Gandara DR, et al.: The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clinical Genitourinary Cancer 2007, 5(7):433-437.
- [32]Baumann M, DuBois W, Pu A, Freeman J, Suit HD: Response of xenografts of human malignant gliomas and squamous cell carcinomas to fractionated irradiation. Int J Radiat Oncol Biol Phys 1992, 23(4):803-809.
- [33]Taghian A, DuBois W, Budach W, Baumann M, Freeman J, Suit H: In vivo radiation sensitivity of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1995, 32(1):99-104.
- [34]Krause M, Wohlfarth J, Georgi B, Pimentel N, Dorner D, Zips D, Eicheler W, Hessel F, Short SC, Joiner MC, et al.: Low-dose hyperradiosensitivity of human glioblastoma cell lines in vitro does not translate into improved outcome of ultrafractionated radiotherapy in vivo. Int J Radiat Biol 2005, 81(10):751-758.
- [35]Taghian A, Budach W, Zietman A, Freeman J, Gioioso D, Ruka W, Suit HD: Quantitative comparison between the transplantability of human and murine tumors into the subcutaneous tissue of NCr/Sed-nu/nu nude and severe combined immunodeficient mice. Cancer Res 1993, 53(20):5012-5017.
- [36]Short S, Mayes C, Woodcock M, Johns H, Joiner MC: Low dose hypersensitivity in the T98G human glioblastoma cell line. Int J Radiat Biol 1999, 75(7):847-855.
- [37]Vink SR, Lagerwerf S, Mesman E, Schellens JH, Begg AC, van Blitterswijk WJ, Verheij M: Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts. Clin Cancer Res 2006, 12(5):1615-1622.
- [38]de Vries NA, Beijnen JH, van Tellingen O: High-grade glioma mouse models and their applicability for preclinical testing. Cancer Treatment Rev 2009, 35(8):714-723.
- [39]Haugland HK, Nygaard SJ, Tysnes OB: Combined effect of alkyl-lysophospholipid and vincristine on proliferation, migration and invasion in human glioma cell lines in vitro. Anticancer Res 1999, 19(1A):149-156.
- [40]Wang FZ, Fei HR, Li XQ, Shi R, Wang DC: Perifosine as potential anti-cancer agent inhibits proliferation, migration, and tube formation of human umbilical vein endothelial cells. Mol Cell Biochem 2012, 368(1-2):1-8.
- [41]Yosifov DY, Todorov PT, Zaharieva MM, Georgiev KD, Pilicheva BA, Konstantinov SM, Berger MR: Erucylphospho-N, N, N-trimethylpropylammonium (erufosine) is a potential antimyeloma drug devoid of myelotoxicity. Cancer Chemotherapy Pharmacology 2011, 67(1):13-25.
- [42]Potier M, Chantome A, Joulin V, Girault A, Roger S, Besson P, Jourdan ML, LeGuennec JY, Bougnoux P, Vandier C: The SK3/K(Ca)2.3 potassium channel is a new cellular target for edelfosine. Br J Pharmacol 2011, 162(2):464-479.